Oncology research focuses on the treatment and prevention of cancer in the body and blood. These clinical trials may evaluate new medications, treatments or interventions for cancer, cancer prevention and methods to reduce side effects from treatment.

Common Types of Cancer:

•    Lung cancer
•    Breast cancer
•    Prostate cancer
•    Colorectal cancer
•    Pancreatic cancer
•    Hematologic (blood) cancers such as lymphoma and leukemia

To learn more about participating in a clinical trial, please contact us at 

1-800-836-0388 or clinical.research@guthrie.org

 

 

Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07)

** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Flatiron Health, Inc.
Details (Identifier #): NCT06605404
Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Internal
Details (Identifier #): NCT05694338
Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses with Placebo as Treatment for Rhinovirus (RV) in Participants with Chronic Obstructive Pulmonary Disease (COPD)
Department: Pulmonary
Diagnosis: Pulmonary (Lung)
Principal Investigator:

Hehn MD, Boyd

Sponsors: Altesa BioSciences, Inc
Details (Identifier #): NCT07610395
Title: A Phase 3 Randomized, Double-Blind, Active-Controlled
Study of Palazestrant with Ribociclib Versus Letrozole with
Ribociclib for the First-Line Treatment of ER+, HER2
Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT07085767
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT06016738
Title: A Phase 3, Multicenter, Randomized, Open-label
Study Evaluating Efficacy of Sotorasib Platinum
Doublet Combination Versus Pembrolizumab
Platinum Doublet Combination as a Front-Line
Therapy in Subjects With Stage IV or Advanced
Stage IIIB/C Nonsquamous Non–Small Cell Lung
Cancers, Negative for PD-L1, and Positive for
KRAS p.G12C (CodeBreaK 202)
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: Amgen Inc.
Details (Identifier #): NCT05920356
Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY)
Department: Pulmonary
Diagnosis: Pulmonary (Lung)
Principal Investigator:

Hehn MD, Boyd

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT06878261
Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Poulose MD, Joyson

Sponsors: Shanghai Henlius Biotech, Inc.
Details (Identifier #): NCT06532006
Title: A012103 OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Details (Identifier #): NCT05812807
Title: ALLIANCE A032302
DOCETAXEL ADDITION IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER
(ASPIRE)
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Basnet MD, Alina

Sponsors: National Cancer Institute
Details (Identifier #): NCT06931340
Showing 1-10 of 29 Results